Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth
Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth
Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline
Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding'
Alkermes Catches A 'Sell' Downgrade On Depression Therapy, M&A Prospects
Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding'
Alkermes Catches A 'Sell' Downgrade On Depression Therapy, M&A Prospects
Goldman Drops Alnylam From Conviction List, But Continues To See 'Blockbuster Potential'
Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying
Terence Flynn Recent News
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
Despite Alexion's Internal Investigation, Goldman Standing Behind Its Buy Rating
What Went Wrong With Alnylam's Revusiran Program?
Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
Goldman Sees A Number Of Catalysts Coming For Amgen Shares
Amgen, Incyte Well Positioned Following Brexit
Amgen's Near-Term Catalyst Is Ph3 IVUS According To Goldman Sachs
Goldman Sachs: 3 Questions For Agios Pharmaceuticals
Goldman Sachs Considers Implications For Regeneron, Amgen, Sanofi Following PCSK9 Ruling
Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs
Goldman Sachs Comments on How Strong Sales of Kyprolis, Epogen, and Prolia Might Affect Amgen
UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data
UPDATE: Goldman Sachs Initiates Agios Pharmaceuticals with Buy on Emerging Leadership Position
UPDATE: Goldman Sachs Downgrades Cubist Pharmaceuticals Following Removal from Conviction List
UPDATE: Goldman Sachs Reiterates Buy Rating, $130 PT on Amgen Ahead of AMG 386 Phase 3 Data